Positive News SentimentPositive NewsNASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Forecast, Price & News $3.95 -0.41 (-9.40%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$3.87▼$4.3650-Day Range$3.11▼$4.4952-Week Range$2.58▼$6.85Volume139,514 shsAverage Volume127,800 shsMarket Capitalization$170.95 millionP/E RatioN/ADividend YieldN/APrice Target$11.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Larimar Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside199.6% Upside$11.83 Price TargetShort InterestHealthy1.39% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.81) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector392nd out of 972 stocksPharmaceutical Preparations Industry164th out of 444 stocks 3.4 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.83, Larimar Therapeutics has a forecasted upside of 199.6% from its current price of $3.95.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.39% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 5.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 3.3 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Larimar Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($0.81) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Larimar Therapeutics (NASDAQ:LRMR) StockLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.Read More LRMR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comLarimar Therapeutics to Present at the Citi 18th Annual BioPharma ConferenceAugust 15, 2023 | markets.businessinsider.comLarimar Therapeutics (LRMR) Receives a Buy from JMP SecuritiesOctober 1, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.August 11, 2023 | seekingalpha.comLarimar Therapeutics GAAP EPS of -$0.34 misses by $0.14August 11, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)August 11, 2023 | markets.businessinsider.comLifeSci Capital Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)August 10, 2023 | finance.yahoo.comLarimar Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsAugust 7, 2023 | finance.yahoo.comLarimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2mOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...July 28, 2023 | bizjournals.comLab Notes: Larimar Therapeutics is once again advancing its lead drug candidate following FDA delayJuly 28, 2023 | seekingalpha.comLarimar, Design higher as they benefit from Biogen deal for ReataJuly 26, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)July 25, 2023 | finance.yahoo.comLarimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension TrialJuly 25, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say AnalystsJuly 19, 2023 | benzinga.comLarimar Therapeutics Chief Medical Officer Awarded $583K Worth of Stock OptionsJuly 17, 2023 | finance.yahoo.comLarimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical OfficerJune 21, 2023 | seekingalpha.comLarimar Therapeutics to join Russell 3000 IndexJune 21, 2023 | finance.yahoo.comLarimar Therapeutics Set to Join Russell 3000® IndexMay 18, 2023 | msn.comGuggenheim Maintains Larimar Therapeutics (LRMR) Buy RecommendationMay 18, 2023 | msn.comCitigroup Maintains Larimar Therapeutics (LRMR) Neutral RecommendationMay 18, 2023 | markets.businessinsider.comWhere Larimar Therapeutics Stands With AnalystsMay 17, 2023 | markets.businessinsider.comLarimar's Ataxia Demonstrated Shows Better-Than-Expected Frataxin Increase, Analyst SaysMay 16, 2023 | msn.comJMP Securities Reiterates Larimar Therapeutics (LRMR) Market Outperform RecommendationMay 15, 2023 | markets.businessinsider.comLifeSci Capital Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)May 15, 2023 | msn.comLarimar Therapeutics Discloses Lower Dose Data Of Investigational Drug For Rare Neurodegenerative Disorder, Shares PlummetMay 15, 2023 | seekingalpha.comLarimar falls 29% after Phase 2 data for lead asset and Q1 financialsMay 15, 2023 | msn.comLarimar Crashes Even after Positive Topline DataSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.83 High Stock Price Forecast$17.00 Low Stock Price Forecast$4.50 Forecasted Upside/Downside+199.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.96% Return on Assets-26.64% Debt Debt-to-Equity RatioN/A Current Ratio14.64 Quick Ratio14.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book1.54Miscellaneous Outstanding Shares43,278,000Free Float41,417,000Market Cap$170.95 million OptionableNot Optionable Beta0.50 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 64)CEO, Pres & Director Comp: $845.63kMr. Michael Celano CPA (Age 64)Sec. & CFO Comp: $562.62kMr. John BermanVP of Fin. & Admin.Ms. Jennifer Spokes JohanssonVP of Regulatory, Quality & LegalDr. Russell G. Clayton Sr. (Age 62)D.O, Chief Medical Officer Dr. Gopi Shankar M.B.A. (Age 52)Ph.D., Chief Devel. Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsSagimet BiosciencesNASDAQ:SGMTPraxis Precision MedicinesNASDAQ:PRAXAcrivon TherapeuticsNASDAQ:ACRVAllakosNASDAQ:ALLKRallybioNASDAQ:RLYBView All CompetitorsInsiders & InstitutionsBarclays PLCBought 25,939 shares on 9/21/2023Ownership: 0.125%CHI Advisors LLCBought 668,203 shares on 8/22/2023Ownership: 7.889%California State Teachers Retirement SystemBought 8,531 shares on 8/21/2023Ownership: 0.020%Wells Fargo & Company MNBought 9,595 shares on 8/15/2023Ownership: 0.023%Citadel Advisors LLCBought 700 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LRMR Stock - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month target prices for Larimar Therapeutics' shares. Their LRMR share price forecasts range from $4.50 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 199.6% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2023? Larimar Therapeutics' stock was trading at $4.13 at the beginning of 2023. Since then, LRMR stock has decreased by 4.4% and is now trading at $3.95. View the best growth stocks for 2023 here. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.02. What is Larimar Therapeutics' stock symbol? Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR." How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Larimar Therapeutics' stock price today? One share of LRMR stock can currently be purchased for approximately $3.95. How much money does Larimar Therapeutics make? Larimar Therapeutics (NASDAQ:LRMR) has a market capitalization of $170.95 million. The company earns $-35,350,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. How can I contact Larimar Therapeutics? Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The official website for the company is larimartx.com. The company can be reached via phone at (844) 511-9056 or via email at investors@larimartx.com. This page (NASDAQ:LRMR) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.